23 Nov 2025
New in #JACCINT: 1-year results from the #CLASPIID trial show #MTEER benefits patients with degenerative MR across all cardiac damage stages 💪 Significant MR & #QoL improvements 🌟 low adverse events ⚡ and low mortality jacc.org/doi/10.1016/j.jcin.…
#vhdMR #TEER @AbdullahAlabcha
1
15
42
6,225
17 Nov 2025
Congratulations @AbdullahAlabcha for this important analysis showing the benefit of mTEER with pascal in patients with primary MR in all stages of extra-mitral cardiac damage, even Stage 4! With the safety of mTEER, it seems that it is never too late to intervene. A big thank you to all the collaborators and coauthors #CLASPIID trial! @MayoClinicCV
15 Nov 2025
Check out our #JACCINT analysis reporting outcomes of #MTEER in #degenerative #MR according to cardiac damage stages .. a post hoc analysis of the #CLASPIID trial🫀
Tremendously grateful for @MayraGuerreroMD mentorship and support
jacc.org/doi/10.1016/j.jcin.…
@JACCJournals #CardioX
1
2
25
9,115
15 Nov 2025
Check out our #JACCINT analysis reporting outcomes of #MTEER in #degenerative #MR according to cardiac damage stages .. a post hoc analysis of the #CLASPIID trial🫀
Tremendously grateful for @MayraGuerreroMD mentorship and support
jacc.org/doi/10.1016/j.jcin.…
@JACCJournals #CardioX
13
49
13,232
31 May 2024
ICYMI: #EchoFirst outcomes from #MTEER #CLASPIID randomized trial for degenerative #vhdMR: #PASCAL system use & smaller flail gaps ➡️ more likely to have mild or less MR at 6 months. bit.ly/3JTxU5Z
#JACCIMG @hahn_rt @DanielKalbacher @TobiasFRuf @SasanRaissi
4
12
4,635
8 May 2024
New #JACCIMG issue is out!
#EchoFirst outcomes from #MTEER #CLASPIID randomized trial for degenerative #vhdMR: #PASCAL system use & smaller flail gaps ➡️ more likely to have mild or less MR at 6 months. bit.ly/3JTxU5Z
@hahn_rt @DanielKalbacher @TobiasFRuf @SasanRaissi
6
22
4,921
18 Dec 2023
The #CLASPIID randomized trial full cohort meets noninferiority endpoints, demonstrating continued safety & effectiveness of the #PASCAL system at 1 yr & confirming the PASCAL system as a beneficial therapy for #DMR pts. bit.ly/3GRoiHr
#JACCINT #MTEER #CardioTwitter
2
5
11
4,672
13 Nov 2023
【#TCT2023】CLASPⅡD試験の1年追跡より、手術リスクが非常に高い変性性僧帽弁閉鎖不全症患者において、Pascal edge-to-edge修復システムを用いた治療は、Mitraclipシステムによる治療と同等の安全性と有効性を示したことが発表されました。
tcross.co.jp/meeting/tct/613…
#テクロスニュース
1
2
1,034
4 Nov 2023
CLASPIID #TCT2023 1y PMR RCT showed <=1 MR 77% overall, 62% in complex anatomy, ve LV remodeling, stable gradient vs #MitraClip. Real-world global #PASCAL registry will show if <=1 MR can improve with experience in PMR #TEER since 1 MR matters. @JACCJournals #JACCINT
5
10
2,317
3 Nov 2023
ICYMI: Dr. @AbdullahAlabcha interviews Dr. Firas Zahr about his #TCT2023 #JACCINT LBCT paper on the one-year outcomes of the #CLASPIID Trial.
📄: bit.ly/3QcUYiL youtu.be/OAVRutxdots?si=fv43…
1
4
3,952
26 Oct 2023
#TCT2023 #JACCINT LBCT SimPub👇🏽
Check out this interview with Dr. Zahr discussing the 1-year outcomes of the #CLASPIID
jacc.org/doi/10.1016/j.jcin.…
@JACCJournals #CardioTwitter #ACCFIT
2
13
4,583
26 Oct 2023
The CLASP IID trial results appear durable at 1 year, within the limitation of somewhat greater attrition in follow-up rates for #PASCAL vs. #MitraClip. Read recent updates to the clinical trial here: bit.ly/3s6M66o #JACCINT #CLASPIID
3
7
4,091
22 Sep 2023
#TCT2023
#DRAGONFLY for Mitral Transcatheter Edge-to-Edge Repair in China
A TEER device by China
Other TEER devices for MV
1.MitraClip (FDA approved). Coapt Trial
2.Pascal ( CE Approved )...ClaspIID Trial
@crfheart
@TCTConference
1
6
14
2,111
14 Sep 2023
#TCT2023
Following 12 Late Breaking RCT to be presented at 2023 TCT
PARTNER 3 Low-Risk
EVOLUT Low Risk
WATCH TAVR
ALIGN-AR
LIFE-BTK
AGENT IDE
PICSO-AMI-I
T-PASS
TRISCEND II
TRILUMINATE
VIVA
CLASPIID
@crfheart
@TCTConference
2
9
19
4,331
12 Jan 2023
Comparación entre sistemas de tratamiento mediante catéteres de la #insuficiencia mitral severa: Estudio CLASP IID, por el Dr. @CMGarmendia
🔗 Léalo bit.ly/3GZdI1L
#Intervencionismo #Mitral #PASCAL #MitraClip #Valvulopatía #CLASPIID #Catéter #EdgeToEdge #Cardiopatía
2
3
318
23 Dec 2022
The #CLASPIID randomized trial meets primary endpoints and demonstrates safety and effectiveness of the #PASCAL system, expanding transcatheter treatment options for #DMR patients. bit.ly/3Vjepqx
#JACCINT #MTEER #CardioTwitter @LindaGillamMD @j_hausleiter
4
16
5,579
29 Nov 2022
Day 2 London Valves highlights. Advances in mitral and tricuspid valve E2E therapies. Updates from CLASPIID and EXPAND G4 data for M-TEER. @RinaldiMd @troyleomd @samdawkins #PCRLV @PCRonline
2
9
21 Sep 2022
Pascal transcatheter mitral repair device performs as well as MitraClip in late-breaking CLASP IID Trial #TEER #Cardiotwitter #TMVR #Structuralheart #TCT2022 #TCT #TCT22 #Pascal #CLASPIID ow.ly/KzlW50KPwFA
2
3
18 Sep 2022
In this video, Dr. @aelsab interviews Dr. D. Scott Lim about the results of the #CLASPIID trial.
📃 #TCT2022 #JACCINT LBCT paper: bit.ly/3Blkz1t
#ACCIC #DMR #MTEER #MitraClip #CardioTwitter youtu.be/xvy9LC8tJXA
2
6
18 Sep 2022
Tonight at 8 pm CEST interview on trial results with dr. Scott Lim PI of #CLASPIID trial. Will be son available at @PCRonline
1
3
7